1stOncology™: Cancer Intelligence Service – Page 14766 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018

On December 21, 2017 Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, reported that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California (Press release, Altimmune, DEC 21, 2017, View Source [SID1234522748]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Altimmune will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with Altimmune, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].

ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018

On December 21, 2017 ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, reported that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018 (Press release, Agilent, 21 21, 2017, View Source [SID1234522747]).

To schedule a meeting with ABIVAX, investors can registeron the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it..">[email protected].

Investor Update

On December 21, 2017 Prima Biomed presented Investor Update (Presentation, Prima Biomed, DEC 21, 2017, View Source [SID1234522742]).

Idorsia forms research collaboration with Roche in the field of cancer immunotherapy

On 20 December 2017, Idorsia Ltd reported that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy (Press release, Hoffmann-La Roche, DEC 20, 2017, View Source [SID1234584171]).

Martine Clozel, M.D. and Chief Scientific Officer of Idorsia, commented: "The preclinical data we have generated leads us to believe that our approach can translate into significant therapeutic benefits for patients. By joining forces, we are combining our advanced drug discovery program together with the cancer immunotherapy expertise of Roche. I am looking forward to the collaboration with our partner to leverage our research and bring compounds through clinical development as soon as possible."

About the terms of the agreement

The parties will collaborate on the discovery of products through the formation of a joint committee, chaired by Idorsia.

Roche will pay Idorsia an upfront payment of CHF 15 million and will have the option to exclusively license Idorsia compounds and compounds resulting from the collaboration, for a further payment of 35 million, after a pre-determined period. After the exercise of its option right, Roche would have the exclusive worldwide right to develop and commercialize the Idorsia and collaboration compounds.

Idorsia will be eligible to receive one-time development and regulatory milestones of up to CHF 410 million. Idorsia will also be entitled to one-time milestones based on sales thresholds, as well as tiered royalties on annual net sales of all products resulting from the collaboration.

10-Q – Quarterly report [Sections 13 or 15(d)]

Spring Bank Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Spring Bank Pharmaceuticals, 2018, DEC 20, 2017, View Source [SID1234527566]).